Overview

Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0

Status:
Recruiting

Trial end date:
2023-07-10

Target enrollment:

Participant gender:

Summary

Single center, non-randomized, Phase 0 study. Sacituzumab Govitecan given preoperatively, followed by craniotomy with surgery or biopsy of brain tumors (GBM and metastatic brain tumors from Breast) and intraoperative tissue collection will follow with contemporaneous CSF (depending on tumor location) and whole blood (serum) sampling.

Phase:

Early Phase 1

Details

Lead Sponsor:

Andrew Brenner
The University of Texas Health Science Center at San Antonio

Collaborators:

Gilead Sciences
Immunomedics, Inc.

Treatments:

Camptothecin
Immunoconjugates